Intravesical chemotherapy with 4′-epi-Adriamycin in patients with superficial bladder tumors

@article{Matsumura1984IntravesicalCW,
  title={Intravesical chemotherapy with 4′-epi-Adriamycin in patients with superficial bladder tumors},
  author={Y Matsumura and Tomoyasu Tsushima and Yujiro Ozaki and J. N. Yoshimoto and Takafumi Akagi and Tsuneaki Obama and Yasutomo Nash and Hiroyuki Ohmori},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1984},
  volume={16},
  pages={176-177}
}
We evaluated the effects of 4′-epi-Adriamycin (EPI), a derivative of Adriamycin (ADR), in intravesical instillation chemotherapy. The patients received two courses of three daily instillations of 50–80 mg EPI dissolved in 30 ml physiological saline on 3 consecutive days, with an interval of 4 days between courses. Full evaluation was possible in 33 of 35 patients with superficial bladder tumors treated with EPI. Complete response was observed in 4 cases and partial response in 14 cases, giving… CONTINUE READING

From This Paper

Figures and tables from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Superficial bladder cancer: state of the art

Cancer Chemotherapy and Pharmacology • 1994

Approaches to the treatment of bladder cancer at Stanford

Cancer Chemotherapy and Pharmacology • 1987
View 1 Excerpt

Intravesical chemotherapy

Cancer Chemotherapy and Pharmacology • 1987
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Urological Cancer Collaborative Group (OUCCG

Y Matsumura, Y Ozaki, H Ohmori, Okayama
Cancer Chemother Pharmacol • 1983

Vigevani A (1975b) Adriamycin (NSC123127): New chemical developments and analogs

F Arcamone, S Penco
Cancer Chemother Rep • 1975

Adriamycin ( NSC - 123127 ) : New chemical developments and analogs

F Arcamone, S Penco, A Vigevani
Cancer Chemother Rep

Similar Papers

Loading similar papers…